EP1622579B1 - Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin - Google Patents

Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin Download PDF

Info

Publication number
EP1622579B1
EP1622579B1 EP04760943A EP04760943A EP1622579B1 EP 1622579 B1 EP1622579 B1 EP 1622579B1 EP 04760943 A EP04760943 A EP 04760943A EP 04760943 A EP04760943 A EP 04760943A EP 1622579 B1 EP1622579 B1 EP 1622579B1
Authority
EP
European Patent Office
Prior art keywords
acid
skin
extract therefrom
aging
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP04760943A
Other languages
German (de)
French (fr)
Other versions
EP1622579A2 (en
EP1622579A4 (en
Inventor
Harish Mahalingam
Christos D. Kyrou
Michael Traudt
Dmitri Ptchelintsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to PL04760943T priority Critical patent/PL1622579T3/en
Priority to EP11160243A priority patent/EP2409681A1/en
Publication of EP1622579A2 publication Critical patent/EP1622579A2/en
Publication of EP1622579A4 publication Critical patent/EP1622579A4/en
Application granted granted Critical
Publication of EP1622579B1 publication Critical patent/EP1622579B1/en
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to methods of using compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin.
  • Such anti-aging active ingredients include, for example, a-hydroxy acids (e.g., lactic, glycolic, citric), b-hydroxy acids (e.g., salicylic; 5-n-octanoylsalicylic aids) and retinoids (retinoic acids; retinol). It is known that these anti-aging active ingredients have a significant disadvantage in that they frequently are associated with consumer discomfort characterized by burning, smarting, itching or sensation of tightness after application. There remains a general need in the cosmetics industry for products that retard or counter aging effects on the skin, and more specifically for products that produce such effects without undesirable side effects:
  • WO 02/49580 A1 discloses compositions and methods for treating hyperpigmentation relying, inter alia, on 3,3'-thiodipropionic acid as an active agent.
  • WO 94/03149 relates to lipid-soluble esters of 3,3'-thiodipropionic acid in cosmetic preparations said to be suitable to counteract aging of the human skin.
  • US 5,780,042 discloses cosmetic and dermatological formulations comprising at least one substance chosen from the group consisting of 2,4-O-furfurylidenesorbitol and alkyl ethers thereof and at least one substance chosen from the group consisting of tocopherols and tocopheryl esters, optionally in combination with an antioxidant such as 3,3'-Thiodipropionic acid
  • BE 1000724 relates to compositions containing dithranole, optionally in combination with 3,3'-thiodipropionic acid for the treatments of psoriasis.
  • the present invention discloses anti-aging compositions containing an effective amount of 3,3'-thiodipropionic acid which, whey applied to human skin, prevent, treat and/or ameliorate various signs of aging at the area or portion of skin to which they are applied.
  • the present invention provides anti-aging benefits to and improves the aesthetic appearance of the skin.
  • the present invention provides compositions and methods for treating skin to ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • the signs of aging are fine wrinkles, coarse wrinkles, laxness, sagging, turgor and/or undereye paffiness.
  • the anti-aging agent is present in the composition at an amount effect to ameliorate the various signs of aging in the area or portion of skin to which it is applied.
  • the anti-aging agent is preferably present at about 0.0001 percentage by weight (wt%) to about 98 wt%, more preferably at about 0.001 wt% to about 30 wt%, and most preferably at about 0.05 wt% to about 10 wt% based on the total weight of the composition.
  • the composition is preferably applied to an affective area of skin for a period of time to improve the aesthetic appearance of the area of skin to which the composition is applied.
  • the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional anti-agents), the targeted improvement as well as other factors known by those skilled in the art.
  • the present invention provides methods for treating skin to ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • compositions disclosed herein are used in methods of ameliorating the following signs of aging skin: fine wrinkles, coarse wrinkles, sallowness, laxness, sagging, turgor and/or undereye puffiness.
  • compositions for use in the context of the present invention comprise a pharmaceutically and/or cosmetically acceptable vehicle to provide bulk and physical form.
  • the vehicle is hypoallergenic, as allergens and other irritating agents exacerbate pigmentation.
  • Suitable vehicles include, but are not limited to, cetyl alcohol, ethanol, glycerin, myristyl palmitate, polyvinyl alcohol, propylene glycol, propanol, and water, and mixtures thereof.
  • the anti-aging agent is admixed with the vehicle(s) along with any other adjuvants or ingredients to form the topical composition.
  • the compositions of the present invention may also include actives in the form of liposomes.
  • the present composition may take any suitable form such as a solution, cream, serum, stick, patch, mask, towelette, lotion, emulsion, ointment or gel.
  • the present composition may optionally have one or more of the following ingredients: anesthetics, antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • anesthetics antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • the present invention may also include conventional cosmetic acitive agents, such as conventional hypopigmenting agents, such as hydroquinone, ascorbic acid (Vitamin C) and/or licorice extract; retinoids, such as retinol or retinoic acid; anti-inflammatory agents, such as bisabolol, anti-acne agents, such as salicylic acid; exfoliants, such as alpha-hydroxy acids, beta-hydroxy acids, keto acids, oxa acids or oxa diacids (disclosed in U.S. Patent Nos. 5,847,003 and 5,834,513 ); ascorbyl-phosphoryl-cholesterol (disclosed in U.S. Patent No.
  • sunscreens such as oxybenzone, octyl methoxycinnamate, octyl salicylate, octocrylene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethane, methylene bis-benzotriazoylteramehtylbuthylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT); or anti-aging agents; or any combination thereof.
  • sunscreens such as oxybenzone, octyl methoxycinnamate, octyl salicylate, octocrylene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethane, methylene bis-benzotriazoylteramehtylbuthylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT); or anti-aging agents; or any combination thereof.
  • Preferred alpha-hydroxy acids include lactic acid, glycolic add, or a mixture thereof.
  • the preferred oxa diadd is 3,6,9-trioxaundecanedioic acid.
  • 3,3'-thiodipropionic acid may be used to enhance the effectiveness of other skin care actives, such as those disclosed above and those skin care actives disclosed in U.S. Patent No. 6,492,326 at col. 5, lines 9 through col. 20, line 50, which is incorporated herein by reference.
  • Ingredient wt% anti-aging agent (3,3'-thiodipropionic acid) 0.001 to 98 pH adjusting agent (e.g. ammonium 0.001 to 4 Humectants (e.g. glycols, glycerols) 0.5 to 15 Thickeners (e.g. gums, starches polymers) 0.1 to 4 Chelating Agents (e.g. EDTA) 0.001 to 0.5 Emollients (e.g. isopropyl myristate, fatty esters) 1 to 10 Silicones (cyclomethicone-pentamer) 0.1 to 15 Preservative (e.g. parabens) 0.01 to 2 Alcohols (e.g.
  • Antioxidants e.g. vitamin E acetate
  • Anti-inflammatory e.g. bisabolol
  • Sunscreen e.g. titanium dioxide/benzophenone-3, Butyl methoxydibenzoylmethane
  • the cosmetic composition includes at least one ingredient selected from the group consisting of: palmatoyl tetrapeptide-3 (available under the trade name RIGIN from Sederma, France), Gymnostemma pentaphyllum and/or an extract therefrom, Stenolama chusana and/or an extract therefrom, Morinda citrifolia and/or an extract therefrom, Butea frondosa and/or an extract therefrom, Luteoline 7-beta-glucoside, Chlorosalicylic Acid, Naringi crenulata and/or an extract therefrom, Methylthioadenosine, Ferutinin, Ilex purpurea and/or an extract therefrom, Asmunda japonica and/or an extract therefrom, Rhapontin, Uncaria gambir and/or an extract therefrom, lopanic acid, Ellagic acid, 2,4,6,3,4-p

Abstract

The present invention relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect an improvement in the aesthetic appearance of skin, particularly, by providing enhancement of the skin thickness.

Description

    BACKGROUND OF THE INVENTION 1. Field of the Invention
  • The present invention relates to methods of using compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin.
  • There is active contemporary interest in the cosmetics industry to develop products that may be applied topically to the skin that provide anti-aging, hydrating, and/or skin texturizing benefits. Cosmetic products, which enhance the appearance of skin, are increasingly in demand. Consumers are interested in mitigating or delaying the signs of aged or photo-aged skin, such as fine lines, wrinkles, drying, and sagging skin. During the aging process, the complexion of the skin, i.e., the color and appearance of the skin, deteriorates slowly from aging and/or exposure to sunlight. Cosmetic surgery can be used as a treatment for aged skin. However, such treatment is costly and carries the risks normally associated with anesthesia and surgery. Alternatively, cosmetic products that provide anti-aging benefits are highly desirable, to both manufacturers and consumers.
  • The number of cosmetic products directed to help the skin of consumers look younger and less wrinkled is steadily increasing. Commonly, such products contain exfoliating acids as active ingredients. Such anti-aging active ingredients include, for example, a-hydroxy acids (e.g., lactic, glycolic, citric), b-hydroxy acids (e.g., salicylic; 5-n-octanoylsalicylic aids) and retinoids (retinoic acids; retinol). It is known that these anti-aging active ingredients have a significant disadvantage in that they frequently are associated with consumer discomfort characterized by burning, smarting, itching or sensation of tightness after application. There remains a general need in the cosmetics industry for products that retard or counter aging effects on the skin, and more specifically for products that produce such effects without undesirable side effects:
  • Also, in spite of the various anti-aging cosmetic products on the market for the treatment of skin, there remains a need for effective anti-aging compositions that can be applied topically to the skin. More particularly, there remains a need for topically applied cosmetic compositions that have anti-aging and skin texture benefits.
  • WO 02/49580 A1 discloses compositions and methods for treating hyperpigmentation relying, inter alia, on 3,3'-thiodipropionic acid as an active agent.
  • WO 94/03149 relates to lipid-soluble esters of 3,3'-thiodipropionic acid in cosmetic preparations said to be suitable to counteract aging of the human skin.
  • US 5,780,042 discloses cosmetic and dermatological formulations comprising at least one substance chosen from the group consisting of 2,4-O-furfurylidenesorbitol and alkyl ethers thereof and at least one substance chosen from the group consisting of tocopherols and tocopheryl esters, optionally in combination with an antioxidant such as 3,3'-Thiodipropionic acid
  • BE 1000724 relates to compositions containing dithranole, optionally in combination with 3,3'-thiodipropionic acid for the treatments of psoriasis.
  • It is an object of the present invention to provide methods for ameliorating the signs of dermatological aging of human skin.
  • It is yet a further object of the present invention to provide methods of using cosmetic compositions that improve the aesthetic appearance of skin and remediate the effects of aging skin and signs of aging on skin.
  • The objects of the present invention are achieved by the methods /the use defined in the annexed claims, comprising topically applying to the skin a composition comprising 3,3'-thiodipropionic acid and a vehicle.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention discloses anti-aging compositions containing an effective amount of 3,3'-thiodipropionic acid which, whey applied to human skin, prevent, treat and/or ameliorate various signs of aging at the area or portion of skin to which they are applied. The present invention provides anti-aging benefits to and improves the aesthetic appearance of the skin. In particular, the present invention provides compositions and methods for treating skin to ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging. The signs of aging are fine wrinkles, coarse wrinkles, laxness, sagging, turgor and/or undereye paffiness.
  • The anti-aging agent is present in the composition at an amount effect to ameliorate the various signs of aging in the area or portion of skin to which it is applied. The anti-aging agent is preferably present at about 0.0001 percentage by weight (wt%) to about 98 wt%, more preferably at about 0.001 wt% to about 30 wt%, and most preferably at about 0.05 wt% to about 10 wt% based on the total weight of the composition. The composition is preferably applied to an affective area of skin for a period of time to improve the aesthetic appearance of the area of skin to which the composition is applied. As can be understood by those in the art, the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional anti-agents), the targeted improvement as well as other factors known by those skilled in the art.
  • In particular, the present invention provides methods for treating skin to ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • The compositions disclosed herein are used in methods of ameliorating the following signs of aging skin: fine wrinkles, coarse wrinkles, sallowness, laxness, sagging, turgor and/or undereye puffiness.
  • The compositions for use in the context of the present invention comprise a pharmaceutically and/or cosmetically acceptable vehicle to provide bulk and physical form. Preferably, the vehicle is hypoallergenic, as allergens and other irritating agents exacerbate pigmentation. Suitable vehicles include, but are not limited to, cetyl alcohol, ethanol, glycerin, myristyl palmitate, polyvinyl alcohol, propylene glycol, propanol, and water, and mixtures thereof. The anti-aging agent is admixed with the vehicle(s) along with any other adjuvants or ingredients to form the topical composition. The compositions of the present invention may also include actives in the form of liposomes.
  • The present composition may take any suitable form such as a solution, cream, serum, stick, patch, mask, towelette, lotion, emulsion, ointment or gel.
  • The present composition may optionally have one or more of the following ingredients: anesthetics, antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • The present invention may also include conventional cosmetic acitive agents, such as conventional hypopigmenting agents, such as hydroquinone, ascorbic acid (Vitamin C) and/or licorice extract; retinoids, such as retinol or retinoic acid; anti-inflammatory agents, such as bisabolol, anti-acne agents, such as salicylic acid; exfoliants, such as alpha-hydroxy acids, beta-hydroxy acids, keto acids, oxa acids or oxa diacids (disclosed in U.S. Patent Nos. 5,847,003 and 5,834,513 ); ascorbyl-phosphoryl-cholesterol (disclosed in U.S. Patent No. 5,866,147 ); sunscreens, such as oxybenzone, octyl methoxycinnamate, octyl salicylate, octocrylene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethane, methylene bis-benzotriazoylteramehtylbuthylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT); or anti-aging agents; or any combination thereof.
  • Preferred alpha-hydroxy acids include lactic acid, glycolic add, or a mixture thereof. The preferred oxa diadd is 3,6,9-trioxaundecanedioic acid.
  • 3,3'-thiodipropionic acid, may be used to enhance the effectiveness of other skin care actives, such as those disclosed above and those skin care actives disclosed in U.S. Patent No. 6,492,326 at col. 5, lines 9 through col. 20, line 50, which is incorporated herein by reference.
    • EXAMPLE
  • Ingredient wt%
    anti-aging agent
    (3,3'-thiodipropionic acid) 0.001 to 98
    pH adjusting agent (e.g. ammonium 0.001 to 4
    Humectants (e.g. glycols, glycerols) 0.5 to 15
    Thickeners (e.g. gums, starches polymers) 0.1 to 4
    Chelating Agents (e.g. EDTA) 0.001 to 0.5
    Emollients (e.g. isopropyl myristate, fatty esters) 1 to 10
    Silicones (cyclomethicone-pentamer) 0.1 to 15
    Preservative (e.g. parabens) 0.01 to 2
    Alcohols (e.g. ethanol) 0 to 10
    Antioxidants (e.g. vitamin E acetate) 0.01 to 5
    Anti-inflammatory (e.g. bisabolol) 0.01 to 10
    Sunscreen (e.g. titanium dioxide/benzophenone-3,
    Butyl methoxydibenzoylmethane) 0.01 to 15
    Water q.s.
  • It is preferred that in addition to 3,3'-thiodipropionic add, the cosmetic composition includes at least one ingredient selected from the group consisting of: palmatoyl tetrapeptide-3 (available under the trade name RIGIN from Sederma, France), Gymnostemma pentaphyllum and/or an extract therefrom, Stenolama chusana and/or an extract therefrom, Morinda citrifolia and/or an extract therefrom, Butea frondosa and/or an extract therefrom, Luteoline 7-beta-glucoside, Chlorosalicylic Acid, Naringi crenulata and/or an extract therefrom, Methylthioadenosine, Ferutinin, Ilex purpurea and/or an extract therefrom, Asmunda japonica and/or an extract therefrom, Rhapontin, Uncaria gambir and/or an extract therefrom, lopanic acid, Ellagic acid, 2,4,6,3,4-pentahydroxychalcone, Ligusticum chianxiong or an extract therefrom, Azadirachta indica (Neem) and/or an extract therefrom, Aframomum melegueata and/or an extract therefrom, 2'amino 4,5-methyl thiazole, or any combination thereof. More preferably, the cosmetic composition contains at least two ingredients selected from the foregoing group.
  • As used herein, singular can mean plural.

Claims (8)

  1. A method for ameliorating the following signs of aging skin: fine wrinkles, coarse wrinkles, laxness, sagging, turgor and/or undereye puffiness,
    comprising topically applying to the skin in need of improvement a cosmetically effective amount of a composition comprising 3,3'-thiodipropionic acid and a vehicle.
  2. The method of claim 1, wherein the 3,3'-thiodipropionic acid is present in an amount of from 0.001 wt% to 30 wt% based on the total weight of the composition.
  3. The method of claim 1, wherein the 3,3'-thiodipropionic acid is present in an amount of from 0.05 wt% to 10 wt% based on the total weight of the composition.
  4. The method of claim 1, wherein the cosmetic composition further comprises an ingredient selected from the group consisting of hydroquinone, ascorbic acid, licorice extract, retinoid, bisabolol, salicylic acid, an oxa acid, oxa diacid, an alpha hydroxy acid, a beta hydroxy acid, a keto acid, and any combination thereof.
  5. The method of claim 4, wherein the ingredient is selected from the group consisting of: lactic acid, glycolic acid, 3,6,9-trioxaundecanedioic acid, and any combination thereof.
  6. The method of claim 1, wherein the cosmetic composition further comprises an ingredient selected from the group consisting of palmatoyl tetrapeptide-3, Gymnostemma pentaphyllum and/or an extract therefrom, Stenolama chusana and/or an extract therefrom, Morinda citrifolia and/or an extract therefrom, Butea frondosa and/or an extract therefrom, Luteoline 7-beta-glucoside, chlorosalicylic Acid, Naringi crenulata and/or an extract therefrom, methylthioadenosine, ferutinin, Ilex purpurea and/or an extract therefrom, Asmunda japonica and/or an extract therefrom, rhapontin, Uncaria gambir and/or an extract therefrom, iopanic acid, ellagic acid, 2,4,6,3,4-pentahydroxychalcone, Ligusticum chianxiong or an extract therefrom, Azadirachta indica (Neem) and/or an extract therefrom, Aframomum melegueata and/or an extract therefrom, 2'amino 4,5-methyl thiazole, or any combination thereof.
  7. The method of claim 1, wherein the vehicle includes water.
  8. Use of 3,3'-thiodipropionic acid as an anti-aging agent for ameliorating the following signs of aging skin: fine wrinkles, coarse wrinkles, laxness, sagging, turgor and/or undereye puffiness by topical application of the agent to the skin.
EP04760943A 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin Active EP1622579B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL04760943T PL1622579T3 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
EP11160243A EP2409681A1 (en) 2003-05-12 2004-05-07 Method for improving the aesthetic appearance of skin by enhancing the skin thickness

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/436,310 US20040067245A1 (en) 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
PCT/US2004/014468 WO2004100889A2 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin

Publications (3)

Publication Number Publication Date
EP1622579A2 EP1622579A2 (en) 2006-02-08
EP1622579A4 EP1622579A4 (en) 2007-12-12
EP1622579B1 true EP1622579B1 (en) 2011-03-30

Family

ID=33449708

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04760943A Active EP1622579B1 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
EP11160243A Withdrawn EP2409681A1 (en) 2003-05-12 2004-05-07 Method for improving the aesthetic appearance of skin by enhancing the skin thickness

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11160243A Withdrawn EP2409681A1 (en) 2003-05-12 2004-05-07 Method for improving the aesthetic appearance of skin by enhancing the skin thickness

Country Status (13)

Country Link
US (3) US20040067245A1 (en)
EP (2) EP1622579B1 (en)
JP (2) JP2006514997A (en)
CN (1) CN1697645A (en)
AT (1) ATE503454T1 (en)
AU (1) AU2004238316B9 (en)
BR (1) BRPI0403036B1 (en)
CA (1) CA2477748C (en)
DE (1) DE602004032018D1 (en)
MX (1) MX282977B (en)
PL (1) PL1622579T3 (en)
TW (1) TWI280139B (en)
WO (1) WO2004100889A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176658D1 (en) * 1981-12-10 1988-03-31 Revlon Process for making metallic leafing pigments
US7189419B2 (en) * 2002-12-17 2007-03-13 Avon Products, Inc. Use of active extracts to lighten skin, lips, hair, and/or nails
US20050136028A1 (en) * 2003-12-19 2005-06-23 Dmitri Ptchelintsev Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
US20070259057A1 (en) * 2004-08-30 2007-11-08 Kao Corporation Wrinkle Reduction Agent, Lipolysis Accelerator, Composition for External Use on Skin, and Food or Beverage Composition
CN101076254B (en) * 2004-12-22 2012-10-31 雅芳产品公司 Method and composition for reducing the appearance of wrinkles
FR2902324B1 (en) * 2006-06-20 2009-04-03 Oreal USE OF ELLAGIC ACID FOR THE TREATMENT OF CANITIA
JPWO2008018133A1 (en) * 2006-08-10 2009-12-24 株式会社ノエビア Moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and external preparation for skin
EP1902756A1 (en) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition and method for treating skin by administering silybin and piperine/terahydropiperine
EP1902755A1 (en) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Cosmetic compositions decreasing GM-CSF release induced by nickel salts
WO2008151890A1 (en) * 2007-06-11 2008-12-18 Chanel Parfums Beaute Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin
JP2011520768A (en) * 2007-06-11 2011-07-21 シャネル パフュームズ ビューテ Cosmetic use of an active agent for stimulating the expression of FN3K and / or FN3KRP for improving the barrier function of the skin
CA2739523A1 (en) 2007-10-01 2009-04-09 The University Of British Columbia Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
CA2739512A1 (en) 2007-10-01 2009-04-09 The University Of British Columbia Granzyme a and granzyme b diagnostics
US20090092561A1 (en) * 2007-10-09 2009-04-09 Lupia Joseph A Body-care and household products and compositions comprising specific sulfur-containing compounds
JP5425413B2 (en) * 2008-05-26 2014-02-26 モリンダ インコーポレーテッド Elastase inhibitor
US7994175B2 (en) * 2008-12-29 2011-08-09 Avon Products, Inc Cosmetic use of 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides and related compounds
MX368365B (en) * 2009-12-22 2019-09-30 Avon Prod Inc Paxillin stimulating compositions and cosmetic uses thereof.
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
JP5850929B2 (en) * 2010-06-30 2016-02-03 エイボン プロダクツ インコーポレーテッド Composition for improving the appearance of the skin by stimulating MAGP-1
EP2838617A2 (en) * 2012-04-20 2015-02-25 The Procter & Gamble Company Compositions and methods for improving the appearance of facial pores
CA2877084C (en) * 2012-08-30 2020-07-21 Avon Products, Inc. Dickkopf-1 expression modulating compositions and uses thereof
US9023327B2 (en) 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof
PL2964334T3 (en) 2013-03-07 2021-10-25 Avon Products, Inc. Compositions and methods for treating damaged hair
WO2014163896A1 (en) * 2013-03-12 2014-10-09 Avon Products, Inc A topical lightening composition and methods of use thereof
KR102020817B1 (en) * 2013-08-14 2019-09-11 주식회사 엘지생활건강 Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation
CN111032203B (en) * 2017-04-03 2022-11-15 欧莱雅 System for forming a cosmetic composition and skin care management system
KR102362617B1 (en) * 2018-05-16 2022-02-11 오오타 유시 가부시키가이샤 Skin photo-aging preventive agent and functional cosmetic containing the same
CN110200883A (en) * 2019-06-19 2019-09-06 武汉百思凯瑞生物科技有限公司 A kind of antiallergic conveys nano-composition and its preparation method and application altogether

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686489A (en) * 1986-12-23 1997-11-11 Tristrata Technology, Inc. Alpha hydroxyacid esters for skin aging
BE1000724A6 (en) * 1987-05-20 1989-03-21 Stiefel Lab Ltd Topical compsns. for psoriasis treatment - contg. dithranol in emulsion base
FR2659554B1 (en) * 1990-03-16 1994-09-30 Oreal COMPOSITION FOR THE COSMETIC AND / OR PHARMACEUTICAL TREATMENT OF THE TOP LAYERS OF THE EPIDERMIS BY TOPICAL APPLICATION TO THE SKIN AND PREPARATION METHOD THEREOF.
CH686285A5 (en) * 1992-08-06 1996-02-29 Beiersdorf Ag Cosmetic or pharmaceutical preparation used to delay the aging of human skin.
DE4305788C2 (en) * 1993-02-25 1997-06-12 Beiersdorf Ag Cosmetic and dermatological formulations to protect the skin against oxidation processes
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
US5866147A (en) 1995-05-15 1999-02-02 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
FR2742750B1 (en) * 1995-12-22 1998-01-30 Oreal NOVEL DERIVATIVES OF L-2-OXOTHIAZOLIDINE 4-CARBOXYLIC ACID AND THEIR USE FOR SKIN CARE
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
US5847003A (en) 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6068848A (en) * 1997-12-17 2000-05-30 Color Access, Inc. Antioxidant mixture comprising tocopherol
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
DE19929511C2 (en) * 1999-06-29 2003-04-10 Cognis Deutschland Gmbh Highly concentrated flowable anionic surfactant mixtures
CA2413919A1 (en) * 2000-03-21 2001-09-13 Avon Products, Inc. Methods using phytol to improve the appearance of skin and compositions for such methods
FR2807323A1 (en) * 2000-04-10 2001-10-12 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING A STEROID AND A 2-ALKYL ALKANOL OR AN ESTER
JP3636973B2 (en) * 2000-06-26 2005-04-06 株式会社カネボウ化粧品 Radical scavengers and cosmetics
US6562321B2 (en) * 2000-12-20 2003-05-13 Avon Products, Inc. Compositions and methods for treating hyperpigmentation
US6500857B1 (en) * 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
DE10132338A1 (en) * 2001-07-04 2003-01-16 Basf Ag Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic products
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use

Also Published As

Publication number Publication date
DE602004032018D1 (en) 2011-05-12
CN1697645A (en) 2005-11-16
WO2004100889A2 (en) 2004-11-25
BRPI0403036B1 (en) 2014-12-16
ATE503454T1 (en) 2011-04-15
JP2009046510A (en) 2009-03-05
JP2006514997A (en) 2006-05-18
AU2004238316A1 (en) 2004-11-25
CA2477748C (en) 2011-12-06
TWI280139B (en) 2007-05-01
US20120315344A1 (en) 2012-12-13
US20040067245A1 (en) 2004-04-08
EP1622579A2 (en) 2006-02-08
MXPA04008328A (en) 2005-02-03
AU2004238316B2 (en) 2007-08-23
EP1622579A4 (en) 2007-12-12
WO2004100889A3 (en) 2005-03-24
MX282977B (en) 2011-01-17
US20140308376A1 (en) 2014-10-16
BRPI0403036A (en) 2005-11-22
TW200505490A (en) 2005-02-16
AU2004238316B9 (en) 2007-08-23
EP2409681A1 (en) 2012-01-25
PL1622579T3 (en) 2011-08-31
US8808765B2 (en) 2014-08-19
CA2477748A1 (en) 2004-11-12

Similar Documents

Publication Publication Date Title
EP1622579B1 (en) Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US11896696B2 (en) Methods of skin whitening by use of canola extracts
EP1351647B1 (en) Compositions and methods for treating hyperpigmentation
EP1827359A2 (en) The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products
EP1536763B1 (en) Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent
US20070238764A1 (en) Use of Sphingoid Base Associated with Nicotinic Acid or a Nicotinic Acid Amide in the Form of Depigmentation Agent
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
JP6255154B2 (en) Topical skin preparation
EP2065031A1 (en) Skin treatment composition
EP1170002A1 (en) Method of reducing the loss of skin elasticity and firmness
KR101733189B1 (en) Composition for promotion of growing nail or toenail
JP2008247787A (en) External preparation for skin
JP2004250368A (en) Agent for improving ultraviolet-induced cell damage
EP4342442A1 (en) Composition with endothelin inhibiting effect, preparation method and use thereof
WO2024056566A1 (en) Use of thioethylamine composition for skin rejuvenation and improved synergistic effect when combined with an organic acid and/or azabenzene-4-carboxamide
JP2010070497A (en) Ceramide production promoter, moisturizer and skin care external preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20071112

17Q First examination report despatched

Effective date: 20090416

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAHALINGAM, HARISH

Inventor name: PTCHELINTSEV, DMITRI

Inventor name: TRAUDT, MICHAEL

Inventor name: KYROU, CHRISTOS, D.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004032018

Country of ref document: DE

Date of ref document: 20110512

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004032018

Country of ref document: DE

Effective date: 20110512

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110701

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20120102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004032018

Country of ref document: DE

Effective date: 20120102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20130606

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140602

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230526

Year of fee payment: 20

Ref country code: DE

Payment date: 20230519

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230428

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230523

Year of fee payment: 20